^
    Back
    Association details:
    Biomarker:AXL overexpression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Eur J Cancer
    Title:

    AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

    Published date:
    08/17/2020
    Excerpt:
    ...in the GSE5851 dataset higher AXL RNA levels correlated with worse PFS with cetuximab in KRAS-exon2 WT chemorefractory patients….AXL is a marker of poor prognosis in mCRC with consistent clinical and preclinical evidences of involvement in primary and acquired resistance to anti-EGFR drugs in RAS WT patients.
    DOI:
    10.1016/j.ejca.2020.07.010